MIEFX Performance — Matthews Emerging Markets Equity Fund, Institutional Class
Data updated: 2026-08-24
MIEFX returned +33.31% year to date and +51.97% over one year to Jun 2026. Annualised returns are +25.38% over 3 years and +8.57% over 5 years. The fund beat its Emerging Markets Equity category average: $100 invested three years ago grew to $197, against $179 for the category, and to $152 over one year, against $141. Volatility over the past three years was 18.15% a year. In the 12 months to Jun 2026 the fund lost a net $29.5M, and assets reached $333.89M.
MIEFX Growth of $100
What $100 invested in Matthews Emerging Markets Equity Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Emerging Markets Equity category average over the same months.
| Period | MIEFX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $152 | $141 |
| 3 years (Jul 2023 – Jun 2026) | $197 | $179 |
| 5 years (Jul 2021 – Jun 2026) | $151 | $144 |
| Since data start (May 2020 – Jun 2026) | $266 | $217 |
MIEFX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +33.31% |
| 1 year | +51.97% |
| 3 years (annualised) | +25.38% |
| 5 years (annualised) | +8.57% |
MIEFX Annual Returns
Calendar-year total returns of Matthews Emerging Markets Equity Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +33.31% |
| 2025 | +29.66% |
| 2024 | +11.38% |
| 2023 | +8.64% |
| 2022 | −20.81% |
| 2021 | −0.43% |
| 2020 (May–Dec) | +61.56% |
MIEFX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.8% | +6.5% | −11.2% | +16.5% | +11.1% | +0.1% | — | — | — | — | — | — |
| 2025 | +1.1% | +1.1% | −0.5% | +0.1% | +5.3% | +6.2% | +1.1% | +2.4% | +7.0% | +3.2% | −2.4% | +2.2% |
| 2024 | −4.7% | +5.5% | +3.5% | −0.7% | +0.9% | +3.6% | −0.9% | +2.8% | +7.8% | −2.5% | −1.7% | −2.1% |
| 2023 | +8.1% | −5.2% | +1.0% | −0.5% | −1.4% | +4.6% | +4.3% | −5.0% | −3.9% | −4.8% | +7.9% | +4.6% |
| 2022 | −1.3% | −7.8% | −2.7% | −6.6% | 0.0% | −8.8% | +3.1% | 0.0% | −8.9% | +2.2% | +13.4% | −3.6% |
| 2021 | +0.4% | +2.9% | −1.8% | +1.6% | +3.5% | +2.4% | −6.2% | +1.1% | −3.4% | +2.5% | −5.6% | +2.6% |
| 2020 | — | — | — | — | +6.1% | +10.0% | +9.9% | +4.3% | −1.3% | +2.5% | +9.4% | +9.1% |
MIEFX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 18.15%
- 3-year Sharpe ratio: 1.15 (vs 4.5% risk-free rate)
- Best month: +16.51% (Apr 2026)
- Worst month: −11.18% (Mar 2026)
MIEFX Fund Flows
Monthly money in and out of Matthews Emerging Markets Equity Fund, from SEC Form N-PORT.
- 12-month net flow: −$29.5M
- 12-month gross sales (incl. reinvestments): $21.0M
- Sales ÷ redemptions: 0.42×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $888K | $4.7M | −$3.8M |
| May 2026 | $1.1M | $3.3M | −$2.2M |
| Apr 2026 | $611K | $3.7M | −$3.1M |
| Mar 2026 | $1.0M | $3.0M | −$1.9M |
| Feb 2026 | $2.3M | $3.5M | −$1.1M |
| Jan 2026 | $2.1M | $4.4M | −$2.3M |
| Dec 2025 | $8.1M | $7.4M | $705K |
| Nov 2025 | $744K | $3.0M | −$2.3M |
| Oct 2025 | $1.1M | $4.3M | −$3.1M |
| Sep 2025 | $1.2M | $2.8M | −$1.6M |
| Aug 2025 | $1.1M | $5.3M | −$4.2M |
| Jul 2025 | $620K | $5.2M | −$4.5M |
MIEFX Assets Under Management
Net assets of Matthews Emerging Markets Equity Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $333.89M |
| 2026-03-31 | $265.33M |
| 2025-12-31 | $262.96M |
| 2025-09-30 | $268.11M |
| 2025-06-30 | $252.15M |
| 2025-03-31 | $240.18M |
| 2024-12-31 | $22.40M |
| 2024-09-30 | $23.29M |
| 2024-06-28 | $21.44M |
| 2024-03-28 | $20.46M |
| 2023-12-29 | $20.90M |
| 2023-09-29 | $22.16M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.